Supporting guide · Breast cancer
What Is My Breast Cancer Subtype?
Breast cancer is not one conversation. Receptor and HER2 status help explain which systemic options and sequencing may be discussed first.
This page helps you orient to tumor biology. It is not a treatment recommendation — and it is not the same as germline genetic counseling.
Direct answer
Your breast cancer subtype comes mainly from pathology testing on biopsy or surgical tissue — especially hormone receptors (ER/PR) and HER2.
Knowing your subtype helps your care team understand:
- which systemic therapy families may belong in the discussion;
- whether treatment might start before or after surgery;
- what additional assays (including some genomic tests) may still matter.
Subtype is one important piece of the decision — not the whole plan. Stage, health, goals, and personal priorities still matter.
The useful next step is not memorizing every assay name. It is confirming your receptor and HER2 status — and asking whether pending results would change the next decision.
The main subtype forks patients hear most often
Start with the map on many pathology reports. Your situation may combine labels (for example HR+ and HER2+). Ask your team to translate your report in plain language.
ER and/or PR positive
Hormone receptor–positive (HR+)
The cancer may respond to endocrine (hormone) approaches. Many people with HR+ disease discuss endocrine therapy as a central part of the plan.
Discussions often include:
- Endocrine therapy — often long-duration
- Whether chemotherapy adds enough benefit in your situation
- Genomic assays (for some early HR+ / HER2− cancers)
Why it matters
HR+ status can change:
- which medicine families lead the conversation;
- how long therapy may continue;
- whether a genomic assay would refine chemo discussions.
If you are also HER2-positive, ask how both labels shape the plan together — not as two unrelated diagnoses.
HER2 testing positive
HER2-positive
HER2-targeted therapy usually belongs in the systemic discussion, often combined with chemotherapy, and sometimes sequenced before or after surgery.
Doctors consider:
- HER2-targeted therapy as part of the plan
- Combinations and duration that fit your stage
- How response before surgery may be monitored, if neoadjuvant therapy is discussed
Why it matters
HER2 status opens a different option family than HR+ alone or triple-negative disease. Ask what the HER2-targeted part is trying to achieve for you.
Borderline or unclear HER2 results sometimes need repeat or reflex testing — ask before locking a major step.
ER, PR, and HER2 negative
Triple-negative (TNBC)
When hormone receptors and HER2 are all negative, chemotherapy often leads the systemic conversation. Immunotherapy may apply in selected situations — ask whether it is relevant for you.
Common discussion points include:
- Chemotherapy regimens and sequencing
- Whether immunotherapy belongs in your plan
- Clinical trial options in some settings
Why it matters
TNBC changes:
- which medicine families are usually discussed first;
- how sequencing before or after surgery may be framed;
- what questions to ask about trials or immunotherapy.
Triple-negative is a biology label — not a single automatic regimen. Ask what fits your stage and goals.
Why does my subtype matter?
Subtype helps guide treatment discussions. It does not choose a treatment by itself.
Your subtype can influence:
Which systemic options are considered
HR+, HER2+, and triple-negative each open different medicine families — endocrine, HER2-targeted, chemotherapy, and immunotherapy in selected cases — rather than one flat drug menu.
Whether treatment may start before or after surgery
Subtype and stage often shape neoadjuvant versus adjuvant sequencing — a breast-distinctive fork before locking the local plan.
Whether to wait for complete results
If receptor or HER2 results are still pending, ask whether major sequencing or surgery decisions should wait until the biology picture is clear.
Subtype answers: “What biology is this cancer?”
Other information — stage, genetics when relevant, health, and goals — answers: “Which plan fits me now?”
Questions patients often ask
Open a question only if it matches what you are wondering.
Is one subtype better than another?
Subtypes behave and are treated differently.
The important question is not: “Which subtype is better?”
It is: “What does my subtype mean for the options we should discuss?”
Does my subtype determine my treatment?
Not by itself. Doctors also consider:
- stage and extent;
- whether therapy starts before or after surgery;
- overall health and life-stage priorities;
- side effects and practical fit;
- personal goals.
Is subtype the same as genetic counseling or BRCA testing?
No. They answer different questions.
Subtype (tumor biology): receptors and HER2 on the cancer itself.
Germline genetics: inherited risk that can change surgery choices for some people.
Ask about both if either could change your next step — but do not treat them as the same test.
What about Oncotype or other genomic assays?
For some early HR+ / HER2− cancers, genomic assays help estimate whether chemotherapy adds enough benefit beyond endocrine therapy.
Not everyone needs this assay. Ask whether the result would change your decision — and when it would be ordered.
Why did my friend with breast cancer get different treatment?
Different plans may happen because cancers differ in:
- subtype;
- stage;
- sequencing;
- genetics;
- personal health and goals.
A treatment that fits one person may not fit another.
Understanding your pathology report
Your pathology report contains important information about your breast cancer’s biology.
You do not need to understand every medical term.
Start by looking for these:
Hormone receptors (ER / PR)
Positive · Negative · Percentage or intensity when listed
Ask: “Am I hormone receptor–positive — and what does that mean for options?”
HER2 status
Positive · Negative · Equivocal / pending repeat testing
Ask: “Is my HER2 result complete and clear?”
Triple-negative wording
When ER, PR, and HER2 are all negative
Ask: “If I am triple-negative, which systemic approaches fit my situation?”
Pending or incomplete biology
Tests ordered · Results pending · Repeat / reflex testing
Ask: “Would pending results change sequencing or surgery timing?”
Bring the report (or a photo/PDF) to your appointment. Confirming receptor and HER2 status is enough to start a clearer conversation.
Questions to take to your doctor
Take to your appointment
Questions to take to your doctor
Before you leave, confirm:
- What is my receptor and HER2 status in plain language?
- Are any subtype results still pending?
- Would pending results change options or sequencing?
- Do I also need germline genetic counseling before surgery?
Add items to your prep sheet— Copy/Print includes this list plus any questions you added below.
Understand my subtype
- Am I HR+, HER2+, triple-negative — or a combination?
- Can you explain the key biology lines on my pathology report?
- Is any testing still incomplete?
Understand treatment impact
- How does my subtype affect systemic options?
- Should treatment start before or after surgery for my subtype?
- Is a genomic assay relevant for my situation?
Plan my next step
- What should I learn about next — sequencing, surgery, or systemic options?
- Do I need genetic counseling before a final surgery choice?
Sources & review
This guide helps patients understand breast cancer subtype as part of decision preparation. It does not replace medical advice.
- National Cancer Institute (NCI)
- NCCN Guidelines for Patients: Breast Cancer
- American Cancer Society (ACS)
- American Society of Clinical Oncology (ASCO)